Tela Bio Net Worth
Tela Bio Net Worth Breakdown | TELA |
Tela Bio Net Worth Analysis
Tela Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tela Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tela Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tela Bio's net worth analysis. One common approach is to calculate Tela Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tela Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tela Bio's net worth. This approach calculates the present value of Tela Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tela Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tela Bio's net worth. This involves comparing Tela Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tela Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Tela Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tela Bio's net worth research are outlined below:
| Tela Bio generated a negative expected return over the last 90 days | |
| Tela Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 58.45 M. Net Loss for the year was (46.66 M) with profit before overhead, payroll, taxes, and interest of 47.27 M. | |
| Tela Bio currently holds about 27.73 M in cash with (40.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.9. |
Tela Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tela Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tela Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Tela Bio Target Price Consensus
Tela target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Tela Bio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Tela analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Tela stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Tela Bio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTela Bio Target Price Projection
Tela Bio's current and average target prices are 2.66 and 9.50, respectively. The current price of Tela Bio is the price at which Tela Bio is currently trading. On the other hand, Tela Bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Tela Bio Target Price
Know Tela Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tela Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tela Bio backward and forwards among themselves. Tela Bio's institutional investor refers to the entity that pools money to purchase Tela Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Perkins Capital Management Inc | 2024-09-30 | 225.2 K | Bank Of Montreal | 2024-09-30 | 191.4 K | Bmo Capital Markets Corp. | 2024-09-30 | 191.4 K | Geode Capital Management, Llc | 2024-09-30 | 174.5 K | Millennium Management Llc | 2024-09-30 | 159.1 K | Renaissance Technologies Corp | 2024-09-30 | 148.9 K | Landscape Capital Management,llc | 2024-09-30 | 143.2 K | Gsa Capital Partners Llp | 2024-09-30 | 112.2 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 106.8 K | Essex Woodlands Health Ventures | 2024-09-30 | 4.1 M | Aigh Capital Management, Llc | 2024-09-30 | 2.5 M |
Follow Tela Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 104.77 M.Market Cap |
|
Project Tela Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.55) | (0.58) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.54) | (0.57) | |
| Return On Equity | (2.84) | (2.70) |
When accessing Tela Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Tela Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tela Bio's profitability and make more informed investment decisions.
Please note, the presentation of Tela Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tela Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tela Bio's management manipulating its earnings.
Evaluate Tela Bio's management efficiency
Tela Bio has return on total asset (ROA) of (0.4064) % which means that it has lost $0.4064 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4204) %, meaning that it created substantial loss on money invested by shareholders. Tela Bio's management efficiency ratios could be used to measure how well Tela Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of January 31, 2025, Return On Tangible Assets is expected to decline to -0.58. In addition to that, Return On Capital Employed is expected to decline to -0.68. At present, Tela Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 250.4 K, whereas Total Assets are forecasted to decline to about 63.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.74 | 0.78 | |
| Tangible Book Value Per Share | 0.66 | 0.69 | |
| Enterprise Value Over EBITDA | (3.23) | (3.39) | |
| Price Book Value Ratio | 7.22 | 4.30 | |
| Enterprise Value Multiple | (3.23) | (3.39) | |
| Price Fair Value | 7.22 | 4.30 | |
| Enterprise Value | 131.2 M | 104.1 M |
The decision-making processes within Tela Bio are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 1.8791 | Revenue | Quarterly Revenue Growth 0.259 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tela Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tela Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tela Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tela Bio Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 29th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Tela Bio Earnings Estimation Breakdown
The calculation of Tela Bio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Tela Bio is estimated to be -0.355 with the future projection ranging from a low of -0.425 to a high of -0.3225. Please be aware that this consensus of annual earnings estimates for Tela Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.42 Lowest | Expected EPS | -0.32 Highest |
Tela Bio Earnings Projection Consensus
Suppose the current estimates of Tela Bio's value are higher than the current market price of the Tela Bio stock. In this case, investors may conclude that Tela Bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Tela Bio's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 4 | 95.24% | -0.42 | -0.355 | -1.69 |
Tela Bio Earnings History
Earnings estimate consensus by Tela Bio analysts from Wall Street is used by the market to judge Tela Bio's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Tela Bio's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Tela Bio Quarterly Gross Profit |
|
Tela Bio Earnings per Share Projection vs Actual
Actual Earning per Share of Tela Bio refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Tela Bio predict the company's earnings will be in the future. The higher the earnings per share of Tela Bio, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Tela Bio Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Tela Bio, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Tela Bio should always be considered in relation to other companies to make a more educated investment decision.Tela Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Tela Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.4 | -0.42 | -0.02 | 5 | ||
2024-08-12 | 2024-06-30 | -0.47 | -0.51 | -0.04 | 8 | ||
2024-05-09 | 2024-03-31 | -0.5 | -0.23 | 0.27 | 54 | ||
2024-03-21 | 2023-12-31 | -0.43 | -0.53 | -0.1 | 23 | ||
2023-11-09 | 2023-09-30 | -0.49 | -0.45 | 0.04 | 8 | ||
2023-08-09 | 2023-06-30 | -0.53 | -0.46 | 0.07 | 13 | ||
2023-05-11 | 2023-03-31 | -0.56 | -0.63 | -0.07 | 12 | ||
2023-03-21 | 2022-12-31 | -0.55 | -0.52 | 0.03 | 5 | ||
2022-11-09 | 2022-09-30 | -0.63 | -0.64 | -0.01 | 1 | ||
2022-08-10 | 2022-06-30 | -0.62 | -0.79 | -0.17 | 27 | ||
2022-05-10 | 2022-03-31 | -0.56 | -0.75 | -0.19 | 33 | ||
2022-03-21 | 2021-12-31 | -0.55 | -0.59 | -0.04 | 7 | ||
2021-11-10 | 2021-09-30 | -0.52 | -0.57 | -0.05 | 9 | ||
2021-08-11 | 2021-06-30 | -0.52 | -0.57 | -0.05 | 9 | ||
2021-05-13 | 2021-03-31 | -0.48 | -0.56 | -0.08 | 16 | ||
2021-03-24 | 2020-12-31 | -0.49 | -0.54 | -0.05 | 10 | ||
2020-11-11 | 2020-09-30 | -0.49 | -0.53 | -0.04 | 8 | ||
2020-08-12 | 2020-06-30 | -0.59 | -0.53 | 0.06 | 10 | ||
2020-05-12 | 2020-03-31 | -0.56 | -0.63 | -0.07 | 12 | ||
2020-03-27 | 2019-12-31 | -0.59 | -1.22 | -0.63 | 106 | ||
2019-12-18 | 2019-09-30 | -0.56 | -0.02 | 0.54 | 96 | ||
2019-08-28 | 2019-06-30 | 0 | -0.47 | -0.47 | 0 |
Tela Bio Corporate Management
| Megan Smeykal | Corporate VP | Profile | |
| Taylor Ocasio | General Secretary | Profile | |
| Antony Koblish | President, Cofounder | Profile | |
| Louisa Smith | Investor Officer | Profile | |
| Skott Greenhalgh | Chief Officer | Profile | |
| Peter Murphy | Chief Officer | Profile | |
| Roberto JD | CFO COO | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tela Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Tela Stock refer to our How to Trade Tela Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tela Bio. If investors know Tela will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tela Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.69) | Revenue Per Share | Quarterly Revenue Growth 0.259 | Return On Assets | Return On Equity |
The market value of Tela Bio is measured differently than its book value, which is the value of Tela that is recorded on the company's balance sheet. Investors also form their own opinion of Tela Bio's value that differs from its market value or its book value, called intrinsic value, which is Tela Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tela Bio's market value can be influenced by many factors that don't directly affect Tela Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tela Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tela Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tela Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.